Psychedelic and Psychoanalytic Therapy: Will They Mesh or Clash?Book tickets
American Psychoanalytic Association
This panel will cover the reemerging paradigm of psychedelic therapy and ask whether—and how—it could mesh with psychoanalysis and psychoanalytic psychotherapy.
Psychedelic therapy is anticipated to receive its first federal approval in 2024 and at least one U.S. State will begin issuing licenses to psychedelic therapy service providers in 2023. What do these developments mean for psychoanalytic psychotherapy? Could they catalyze or validate psychoanalytic processes and treatment? Does psychedelic therapy threaten the market share of the traditional psychoanalyst, or does it present an opportunity for psychoanalysis to modernize? The panel will address these topics and more in a timely dialogue with Professor Robin Carhart-Harris and Dr. Donald Moss, followed by audience Q+A.
Professor Carhart-Harris is Director of the new Psychedelics Division within the translational neuroscience center, Neuroscape, at the University of California, San Francisco.
Dr. Donald Moss is the Chair of the American Psychoanalytic Association’s Program Committee.
After attending the Psychoanalysis and Psychedelics Symposium, attendees should be able to:
1) Describe how psychedelic drugs work on the mind.
2) Discuss how the effect of psychedelic drugs might enhance psychoanalytic treatments.
3) Discuss how the use of psychedelic drugs can illuminate clinical and theoretical premises about the structure and meanings of psychic fantasies.
This program will offer 2 Continuing Education Credits.